Pds biotech announces preclinical influenza data to be presented in symposium at immunology2025™ annual meeting

Princeton, n.j., april 16, 2025 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech” or the “company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel infectimune® based flu vaccine will be featured in a symposium on universal influenza vaccines at the american association of immunologists' immunology2025™ annual meeting, taking place may 3-7, 2025, in honolulu, hawaii.
PDS Ratings Summary
PDS Quant Ranking